Target
MYCN
5 abstracts
Abstract
PP2A activation as a new therapeutic strategy in neuroblastoma: Making sense out of senescence.Org: Atux Iskay LLC,
Abstract
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.Org: Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung GmbH, Schneider Children‘s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Paediatric Haematology Oncology, Jagiellonian University Medical College, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Karolinska Institutet, Childhood Cancer Research Unit,
Abstract
Ultrasensitive detection and monitoring of central nervous system tumors from plasma using personalized whole-genome ctDNA profiling.Org: NYU Langone Health, New York, NY, C2i Genomics Ltd., C2i Genomics Inc., Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Clinical characterization of MYC family proto-oncogene amplification in solid tumors from Chinese patients.Org: TangShan Central Hispital, Nanjing Simcere Medical Laboratory Science Co., Ltd., The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd,